Literature DB >> 2228021

Evidence of a role for TNF-alpha in cytolysis by CD4+, class II MHC-restricted cytotoxic T cells.

J P Tite1.   

Abstract

Variants of the tumour necrosis factor (TNF)-sensitive cell lines BALB/c 3T3 and WEHI-164/13 were generated by selection in high concentrations of recombinant TNF-alpha. The selected cells were highly resistant to cytolysis by both TNF-alpha and TNF-beta (lymphotoxin); however, there was no significant difference in sensitivity to killing by class I major histocompatibility complex (MHC)-restricted cytotoxic T lymphocytes (CTL). Resistance to TNF-mediated lysis was, however, accompanied by increased resistance to cytolysis by CD4+ class II-restricted CTL. Furthermore, cytolysis of WEHI-164/13 cells by CD4+ was completely inhibited by anti-TNF antiserum. These data strongly suggest a role for TNF in killing by CD4+ class II MHC-restricted CTL but not in class I MHC-restricted killing.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2228021      PMCID: PMC1384305     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  11 in total

1.  Role of T-cell function in recovery from murine influenza infection.

Authors:  K L Yap; T J Braciale; G L Ada
Journal:  Cell Immunol       Date:  1979-03-15       Impact factor: 4.868

2.  Differential requirement for protein synthesis in cytolysis mediated by class I and class II MHC-restricted cytotoxic T cells.

Authors:  J P Tite
Journal:  Immunology       Date:  1990-08       Impact factor: 7.397

3.  Protein-antigen specific Ia-restricted cytolytic T cells: analysis of frequency, target cell susceptibility, and mechanism of cytolysis.

Authors:  J P Tite; M B Powell; N H Ruddle
Journal:  J Immunol       Date:  1985-07       Impact factor: 5.422

4.  Identification of a unique B-cell-stimulating factor produced by a cloned dendritic cell.

Authors:  C Clayberger; R H DeKruyff; R Fay; H Cantor
Journal:  Proc Natl Acad Sci U S A       Date:  1985-01       Impact factor: 11.205

5.  Rapid colorimetric assay for cell viability: application to the quantitation of cytotoxic and growth inhibitory lymphokines.

Authors:  L M Green; J L Reade; C F Ware
Journal:  J Immunol Methods       Date:  1984-05-25       Impact factor: 2.303

6.  The Lyt phenotype of a long-term allospecific T cell line. Both helper and killer activities to IA are mediated by Ly-1 cells.

Authors:  S L Swain; G Dennert; S Wormsley; R W Dutton
Journal:  Eur J Immunol       Date:  1981-03       Impact factor: 5.532

7.  Purification and properties of cytoplasmic granules from cytotoxic rat LGL tumors.

Authors:  P J Millard; M P Henkart; C W Reynolds; P A Henkart
Journal:  J Immunol       Date:  1984-06       Impact factor: 5.422

8.  H-2 compatibility requirement for virus-specific T cell-mediated effector functions in vivo. I. Specificity of T cells conferring antiviral protection against lymphocytic choriomeningitis virus is associated with H-2K and H-2D.

Authors:  R M Zinkernagel; R M Welsh
Journal:  J Immunol       Date:  1976-11       Impact factor: 5.422

9.  A novel serine esterase expressed by cytotoxic T lymphocytes.

Authors:  M S Pasternack; H N Eisen
Journal:  Nature       Date:  1985 Apr 25-May 1       Impact factor: 49.962

10.  Expression of specific cytolytic activity by H-2I region-restricted, influenza virus-specific T lymphocyte clones.

Authors:  A E Lukacher; L A Morrison; V L Braciale; B Malissen; T J Braciale
Journal:  J Exp Med       Date:  1985-07-01       Impact factor: 14.307

View more
  11 in total

1.  Inhibition of T-cell mediated cytotoxicity by Novobiocin suggests multiple pathways for both CD4+ and CD8+ cytotoxic T cells.

Authors:  P J Wood; A G Stansfield
Journal:  Immunology       Date:  1992-07       Impact factor: 7.397

2.  Clonal analysis of the relationship between class II MHC-restricted cytolysis and lymphokine secretion in murine L3T4+ T cells.

Authors:  X M Gao; F Y Liew; K Bottomly; A Meager; J P Tite
Journal:  Immunology       Date:  1991-02       Impact factor: 7.397

3.  Vaccination Produces CD4 T Cells with a Novel CD154-CD40-Dependent Cytolytic Mechanism.

Authors:  Rhea N Coler; Thomas Hudson; Sean Hughes; Po-Wei D Huang; Elyse A Beebe; Mark T Orr
Journal:  J Immunol       Date:  2015-08-21       Impact factor: 5.422

4.  Major histocompatibility complex class II-restricted cytotoxicity by self-myelin basic protein-reactive T-cell hybridomas: evidence for a tumour necrosis factor-independent nucleolytic mechanism.

Authors:  D C Rayner; L D Petrycky-Cox; M Diocee; E Rector
Journal:  Immunology       Date:  1993-02       Impact factor: 7.397

5.  Simian virus 40 large-T-antigen-specific rejection of mKSA tumor cells in BALB/c mice is critically dependent on both strictly tumor-associated, tumor-specific CD8(+) cytotoxic T lymphocytes and CD4(+) T helper cells.

Authors:  O Utermöhlen; C Schulze-Garg; G Warnecke; R Gugel; J Löhler; W Deppert
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

6.  Multifaceted inhibition of anti-tumour immune mechanisms by soluble tumour necrosis factor receptor type I.

Authors:  C L Selinsky; K L Boroughs; W A Halsey; M D Howell
Journal:  Immunology       Date:  1998-05       Impact factor: 7.397

7.  Role and specificity of T-cell subsets in spontaneous recovery from Friend virus-induced leukemia in mice.

Authors:  M N Robertson; G J Spangrude; K Hasenkrug; L Perry; J Nishio; K Wehrly; B Chesebro
Journal:  J Virol       Date:  1992-06       Impact factor: 5.103

8.  In vivo lymphokine production in experimental autoimmune uveoretinitis.

Authors:  D G Charteris; S L Lightman
Journal:  Immunology       Date:  1993-03       Impact factor: 7.397

9.  Biological response modifiers (BRM) as antigens. III. T cell lines specific for BRM kill tumor cells in a BRM-specific manner.

Authors:  S Ozaki; T Okazaki; K Nakao
Journal:  Cancer Immunol Immunother       Date:  1995-04       Impact factor: 6.968

10.  In vivo detection of dendritic cell antigen presentation to CD4(+) T cells.

Authors:  E Ingulli; A Mondino; A Khoruts; M K Jenkins
Journal:  J Exp Med       Date:  1997-06-16       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.